TY - JOUR T1 - Post-Vaccination Symptoms after A Third Dose of mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease JF - medRxiv DO - 10.1101/2021.12.05.21266089 SP - 2021.12.05.21266089 AU - Dalin Li AU - Philip Debbas AU - Susan Cheng AU - Jonathan Braun AU - Dermot P.B. McGovern AU - Gil Y. Melmed Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/07/2021.12.05.21266089.abstract N2 - Symptoms after SARS-CoV-2 primary vaccination among patients with inflammatory bowel disease (IBD) are generally of similar frequency, severity, and duration to those reported in the general population. The symptom profile after a 3rd mRNA vaccine dose in the predominantly immune-compromised IBD population is unknown. We aimed to assess symptomology after a 3rd or booster dose of mRNA vaccination in adults with IBD. We surveyed participants of the Coronavirus Risk Associations and Longitudinal Evaluation in IBD (CORALE-IBD) post-vaccination registry for symptom frequency and severity after a 3rd mRNA vaccine dose in an observational cohort study. In total, 524 participants (70% female, mean age 45 years) reported a third dose of mRNA vaccination through October 11, 2021. Overall, 41% reported symptoms after a third dose, with symptoms generally more frequent and more severe among participants younger than 55 years. The most frequent postvaccination symptoms were injection site pain (39%), fatigue or malaise (34%), and headache (23%). These symptoms were all less frequently reported after dose 3 than after dose 2. Gastrointestinal symptoms were reported by 8.8%, which was slightly more frequent than after dose 2 (7.8%). Those with severe symptoms after dose 2 were more likely to have severe symptoms after dose 3. These findings can reassure the IBD patient and provider communities that the likelihood and distribution of symptoms after a third mRNA vaccine dose are generally similar to those after a second dose, and that the frequency of postvaccination symptoms after dose 3 are generally lower than after dose 2.Competing Interest StatementGYM has consulted for AbbVie, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda, Techlab, and has received research funding from Pfizer for an unrelated investigator-initiated study. JB has received research funding from Janssen. JCP, JLS, and ECF work for Abbott Diagnostics, a company that performed the serological assays on the biospecimens that were collected for this study. DPBM: Bridge Biotherapeutics, Gilead, Palatin, Pfizer, Promteheus Biosciences, Prometheus Laboratories, Takeda. MC: Abbvie, Arena, Bristol-Meyers Squibb, Janssen, Medtronic, Pfizer, and Takeda. EC: Abbvie and Pfizer. DF: Pfizer. CH: Abbvie, Janssen and Pfizer. DL: Abbvie, Janssen and Takeda. RM: Abbvie, Bristol Myers Squibb, Pfizer, and Prometheus Bioscience. NP: Pfizer. DW: Abbvie, Arena, Bristol Meyers Squibb, Corevitas, Janssen, Lilly, Pfizer, and Takeda. BM: Abbvie, Bristol Myers Squibb, Janssen, Pfizer and Takeda. SG: Abbvie, Janssen, and Takeda. CH: Abbvie, Bristol Meyers Squibb, Genentech, InbDex Pharmaceuticals, Janssen, Lilly, and Pfizer. GS: research funding for unrelated investigator study from Pfizer. ST: Prometheus Bioscience.Funding StatementThis study was supported by the The Leona M. and Harry B. Helmsley Charitable Trust, the Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, and the National Institute of Diabetes and Digestive and Kidney Disease Grants P01DK046763 and U01DK062413. This study has been additionally supported by the Cedars-Sinai Precision Health Initiative, and the Erika J. Glazer Family Foundation. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Cedars-Sinai gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -